Oncologist: Patients with locally advanced rectal cancer (LARC) treated with complete neoadjuvant therapy (TNT) did not improve prognosis

Complete neoadjuvant therapy (TNT) improves tumor response in patients with locally advanced rectal cancer (LARC) compared with neoadjuvant chemoradiotherapy alone
.

However, the effect of TNT on patient survival has not been adequately studied

Complete neoadjuvant therapy (TNT) improves tumor response in patients with locally advanced rectal cancer (LARC) compared with neoadjuvant chemoradiotherapy alone

The study retrospectively included 311 patients who received neoadjuvant chemoradiotherapy (ChemoRT) + surgery + adjuvant chemotherapy, while 313 patients received TNT (fluorouracil and oxaliplatin-based chemotherapy) as neoadjuvant chemotherapy followed by radiotherapy in neoadjuvant therapy.
chemotherapy) ± surgery
.

The CR rate after neoadjuvant therapy was evaluated in the two groups, and the disease-free survival (DFS), local recurrence-free survival, distant metastasis-free survival and overall survival were compared between the two groups

The study retrospectively included 311 patients who received neoadjuvant chemoradiotherapy (ChemoRT) + surgery + adjuvant chemotherapy, while 313 patients received TNT (fluorouracil and oxaliplatin-based chemotherapy) as neoadjuvant chemotherapy followed by radiotherapy in neoadjuvant therapy.

The average age of the patients in the ChemoRT group was older than that in the TNT group (P<0.
001); the proportion of cT4 patients and lymph node positive in the TNT group was higher than that in the chemoRT group
.

The 2-year overall CR rate (pathologic CR or cCR) was higher in the TNT group than in the ChemoRT group (27% vs.

The average age of the patients in the ChemoRT group was older than that in the TNT group (P<0.

Median follow-up was similar in both groups: 4.

We found that across the entire cohort, complete responders had significantly improved DFS compared with incomplete responders (Wald and log-rank P<0.
0001), and also in the ChemoRT (log-rank P=0.
016) and TNT groups Same (log-rank P<0.
0001).

We found that across the entire cohort, complete responders had significantly improved DFS compared with incomplete responders (Wald and log-rank P<0.
0001), and also in the ChemoRT (log-rank P=0.
016) and TNT groups The same (log-rank P<0.
0001).
We found that in the entire cohort, complete responders had significantly improved DFS compared with incomplete responders (Wald and log-rank P<0.
0001), and also in the ChemoRT group (log -rank P = 0.
016) as well as the TNT group (log-rank P < 0.
0001).

Univariate analysis found that DFS was not significantly associated with the type of neoadjuvant therapy (HR=1.
3; 95%CI 0.
93-1.
80; P=0.
11)
.

Univariate analysis found that DFS was not significantly associated with the type of neoadjuvant therapy (HR=1.
3; 95%CI 0.
93-1.
80; P=0.
11)
.

Univariate analysis found that DFS was not significantly associated with the type of neoadjuvant therapy (HR=1.

In conclusion, the study showed that the application of TNT modality in patients with locally advanced rectal cancer (LARC) did not improve prognosis, but the high response rate may give more patients the opportunity to preserve the rectum
.

In conclusion, the study showed that the application of TNT modality in patients with locally advanced rectal cancer (LARC) did not improve prognosis, but the high response rate may give more patients the opportunity to preserve the rectum
.

Studies have shown that the use of TNT modality in patients with locally advanced rectal cancer (LARC) did not improve prognosis, but a high response rate may give more patients the opportunity to preserve the rectum

Original source:

Original source:

Kim JK, Marco MR, Roxburgh CSD,  et al .

Kim JK, Marco MR, Roxburgh CSD,  et al .
Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.
Oncologist.
2022 Mar 12:oyac025.
doi: 10.
1093/oncolo/oyac025.
Epub ahead of print.
PMID: 35278070.
Kim JK, Marco MR, Roxburgh CSD,  et al .
Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.
Oncologist.
2022 Mar 12:oyac025.
doi: 10.
1093/oncolo/oyac025.
Epub ahead of print.
PMID: 35278070.
Leave a message here